FDA Approves First and Only Medicine to Treat Cause of Narcolepsy Type 1

FDA Approves First Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms

Registration Now Live: 2026 Bridging Perspectives Conference

Wake Up Narcolepsy Announces AASM Foundation 2026 Grant Update

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy

Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

Wake Up Narcolepsy Selected as July’s Hannaford Community Bag Program Beneficiary

Showcasing Community Voices at the 2026 SLEEP Meeting

Findings From the Institute for Clinical and Economic Review (ICER) Now Available

Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia